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ABSTRACT
Background
An estimated 20%–40% of cancer patients will develop
brain metastases. Whole-brain radiotherapy (WBRT) is
the standard treatment for patients with brain
metastases. Although WBRT can reduce neurologic
symptoms, the median survival following WBRT is be-
tween 3 and 6 months. Given this limited survival, it is
important to consider quality of life (QOL) when treat-
ing patients with brain metastases. However, few stud-
ies have focused on QOL and improvement in
patient-rated symptoms as primary outcomes.
Objective
For an accurate measurement of the extent to which
previous trials have utilized QOL tools to evaluate the
efficacy of WBRT for treatment of brain metastases,
we undertook a literature review to examine the com-
mon endpoints and QOL instruments used.
Methods
We conducted a systematic search using the MEDLINE
(1950 to December 2007) and Cochrane Central Reg-
ister of Controlled Trials (4th quarter 2007) databases.
Eligible studies investigated WBRT in one of the study
arms. The following outcomes were included: median
survival, overall survival, neurologic function, 1-year
local control, and overall response; use of QOL instru-
ments, performance status scales, and neurologic func-
tion assessments; and use of other assessment tools.
Patient-rated QOL instruments were defined as those
that strove to assess all dimensions of QOL; observer-
rated performance instruments such as the Karnofsky
performance status (KPS) were deemed to be perform-
ance scales.
Results
We identified sixty-one trials that included WBRT as a
treatment for brain metastases. Of these sixty-one trials,
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nine evaluated the treatment of a single brain metasta-
sis, and fifty-two evaluated the treatment of multiple
brain metastases. Although fifty-five of the trials em-
ployed a QOL instrument, few trials focused on QOL as
an outcome. We found 23 different instruments used to
evaluate QOL. The most commonly employed instru-
ment was the KPS (n = 33), followed by various neuro-
logic function classification scales (n = 21). A
preponderance of the studies used 1 (n = 26, 43%) or 2
(n = 21, 34%) QOL instruments.
A total of fourteen published trials on brain
metastases included an evaluation of the study popula-
tion’s QOL. Those trials included three that used the
Functional Assessment of Cancer Therapy–General
scale and Brain subscale instrument, three that used
the European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire (C30) and the
Brain Cancer Module 20 instrument, two that used
study-designed QOL instruments, one that used the
Edmonton Symptom Assessment Scale, two that used
the Spitzer Quality of Life index, and three that used
the KPS to evaluate QOL. Some trials reported deterio-
ration in QOL after WBRT in patients with poorer prog-
nosis; other trials detected an improvement in QOL after
WBRT in patients with better prognosis.
Conclusions
To date, fourteen trials in brain metastases that have
included an evaluation of the study population’s QOL
have been published. Although some studies showed
that certain parameters of QOL deteriorate after WBRT,
other studies showed that QOL in patients with better
prognosis is improved after WBRT. Because a stand-
ard, validated QOL instrument has not been used for
this patient population, a comparison of findings con-
cerning QOL between the studies is difficult. The present
review emphasizes the need to include QOL measures
in future WBRT clinical trials for brain metastases.
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1. INTRODUCTION
Brain metastases are a cause of significant morbidity.
An estimated 20%–40% of cancer patients will develop
brain metastases during their illness 1. The most com-
mon primary cancers that metastasize to the brain are
lung, breast, and gastrointestinal cancers 2,3. Depend-
ing on the location of the brain metastases, patients
may suffer from neurologic symptoms that include
headaches, focal weakness, mental disturbances, be-
havioural changes, seizures, speech difficulty, and
ataxia 4. The prognosis for patients with brain
metastases is generally poor; median survival is 1 month
for patients not receiving treatment. Use of corticost-
eroids to reduce cerebral edema has been associated
with symptom improvement 2.
Whole-brain radiotherapy (WBRT) is the standard
treatment for brain metastases. About 30%–40% of af-
fected patients present with a single brain metastasis, but
most present with multiple lesions 5. The objective of
WBRT is to provide symptomatic relief, to allow for ta-
pering of the dose of corticosteroids, and to possibly im-
prove survival. Although many trials have shown that
WBRT can reduce neurologic symptoms, median survival
following a diagnosis of brain metastases is generally
only 3–6 months 6. Patients with a solitary brain metasta-
sis, good performance status, and controlled extracranial
disease may be considered for more aggressive treat-
ment such as surgery with postoperative radiotherapy or
stereotactic radiosurgery. Radiosensitizers, chemotherapy,
and various radiotherapy dose fractionation schedules have
also been explored to improve the outcome of brain
metastases 7–11.
The World Health Organization (WHO) describes
health as a “state of complete physical, mental, and
social well-being and not merely the absence of dis-
ease or infirmity” 12. This subjective, multidimensional
definition of health encourages health care profession-
als to focus not only on a patient’s length of life, but
also his or her quality of life (QOL). Quality of life can
be seen as a balance between minimizing treatment
risks and maximizing benefits, including physical and
psychological effects 13. Because patients with brain
metastases have limited survival, treatment options that
are less morbid and that maximize QOL are essential.
An Outcomes Working Group was formed by the
Health Services Research Committee in the Ameri-
can Society of Clinical Oncology to define the outcomes
of cancer treatment that should be considered for as-
sessment and cancer treatment guidelines. Quality of
life was rated as an endpoint secondary in importance
only to survival. The group suggested that these two
patient outcomes—survival and QOL—should take
precedence over cancer outcomes such as response
rate 14. The importance of including QOL as a compo-
nent of treatment assessment was also emphasized by
Tannock, who wrote, “When cure is elusive, it is time
to start treating the patient and not the tumor” 15.
Previous clinical trials have defined the efficacy
of treatment using some of the following endpoints:
survival, response, radiologic or imaging response,
observer-rated neurologic symptoms, time to recurrence
of intracranial disease, cause of death, and preserva-
tion of the ability to function independently 16–21. How-
ever, few studies have focused on QOL and improvement
in patient-rated symptoms as primary outcomes.
To accurately measure the extent to which previ-
ous trials utilized QOL tools to evaluate the efficacy of
radiotherapy for treatment of brain metastases, we
undertook a literature review to examine the common
endpoints and QOL instruments used.
A preponderance of the published trials used a per-
formance status scale such as the Karnofsky perform-
ance status (KPS) to quantify the general well-being of
patients with brain metastases 19,22–25. The purpose of
a performance status assessment is to quantify a pa-
tient’s level of function, level of ambulation, and abil-
ity for self-care 26. The KPS is rated in increments of
10 on a scale of 0 to 100, with 100 meaning “normal,
no complaints, no signs of disease” and 0 meaning
“death”. A score is assigned based on assessment by an
observer such as a physician, nurse, or researcher 27.
Trials often use a performance score to describe their
study population or as a component of the study’s ex-
clusion criteria—for example, patients below a cer-
tain KPS score are deemed ineligible 28,29.
Although performance status is one of the dimen-
sions of QOL, QOL is subjective and should reflect how a
patient feels 30. The KPS was evaluated previously, and
although it was found to be a reliable instrument, it did
not capture the overall concept of QOL 31–33. In the present
study, only patient-rated instruments that strive to as-
sess all dimensions of QOL were deemed to be QOL
instruments; observer-rated performance instruments
such as the KPS were deemed to be performance scales.
2. METHODS
2.1 Search Strategy
We conducted a systematic search of the MEDLINE
(1950 to December 2007) and Cochrane Central Reg-
ister of Controlled Trials (4th quarter 2007) databases.
The terms “brain neoplasms” and “brain metastas#s”
were used. The subheading “secondary” was selected
to narrow the search to metastases to the brain (so as
to exclude primary brain cancer). That search was
combined with the terms “radiotherapy” or “quality of
life.” Relevant articles and abstracts were reviewed,
and the reference lists from these sources were manu-
ally searched for additional relevant trials. The search
was not limited by year of publication.
2.2 Inclusion Criteria
Articles were included in the literature review if they
met these criteria:
￿ Population   Studies of adult participants who
had been diagnosed with one or more brainWONG et al.
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metastases by computed tomography or magnetic
resonance imaging.
￿ Intervention   WBRT in one study arm.
￿ Type of study   Randomized or quasi-randomized
trials and prospective or retrospective cohort studies.
￿ Outcomes   Survival, QOL, symptom control, neu-
rologic function, toxicity, response of brain
metastases to treatment, cause of death, duration of
functional independence, and intracranial progres-
sion-free duration.
2.2 Exclusion Criteria
Articles were excluded from the literature review if
they were
￿ individual case reports or review articles,
￿ published in languages other than English, or
￿ phase I and II trials for which phase III trials were
already available.
2.3 Data Extraction
The following information extracted from the studies:
￿ Number of patients accrued and evaluated in each
study arm
￿ Patient inclusion and exclusion criteria for studies
that included chemotherapy, surgery, or radiosur-
gery in one study arm
￿ Treatment details such as chemotherapy drugs or
radiosensitizer
￿ Total dose and fractionation schedule for WBRT
trials
￿ Outcomes such as median survival, overall sur-
vival, neurologic function, 1-year local control, and
overall response
￿ Use of QOL instruments, performance status scales,
and neurologic function assessments
￿ Other assessment tools, if used
3. RESULTS
We identified sixty-one trials that treated patients us-
ing WBRT in at least one study arm.
3.1 Single Brain Metastasis
Nine of the sixty-one studies evaluated treatment of
patients with a solitary brain metastasis. Two published
trials and one abstract examined the role of surgery
and WBRT as compared with WBRT alone 23,29,34. One
trial assessed the effectiveness of surgery and WBRT
as compared with surgery alone 19. Epstein et al. 35
compared survival outcomes of various dose escala-
tion schedules. One multi-institutional retrospective
study investigated the use of radiosurgery and WBRT 36.
A study by Jyothirmayi et al. 37 examined the efficacy
of radiosurgery at diagnosis, radiosurgery and WBRT at
diagnosis, and radiosurgery at recurrence. Another
study compared the outcomes of radiosurgery alone,
WBRT alone, and radiosurgery with WBRT 38. Roos et
al. 39 investigated the results of randomizing patients
to WBRT or observation after the patients had been
treated with surgery or radiosurgery. Their study also
examined the QOL of the study population.
3.2 Multiple Brain Metastases
We identified fifty-two studies involving treatment of
multiple brain metastases. One trial examined the use
of corticosteroids and WBRT as compared with WBRT
alone 40. In another trial, all patients received dexam-
ethasone before WBRT, after which they were
randomized to WBRT with a dose of dexamethasone or
to WBRT alone 41. Two retrospective trials examined
the outcomes of multiple treatments including WBRT,
surgery, chemotherapy, or supportive care 42,43.
Twelve studies examined the use of various WBRT
dose fractionation schedules 6,10,22,28,44–51, and seven
trials assessed the efficacy of radiosensitizers and
WBRT as compared with WBRT alone 9,21,24,25,52–54.
Chemotherapy and WBRT were compared in eight
studies 7,8,55–60. Five trials examined the efficacy of
whole-brain re-irradiation in patients with brain
metastases 61–65. One study randomized patients with
1–3 brain metastases to WBRT or WBRT followed by
stereotactic radiosurgery boost 18. One retrospective
study examined the outcomes of WBRT or Gamma Knife
radiosurgery 66. One randomized trial examined the
combination of WBRT and radiosurgery as compared with
WBRT alone for patients with 2–4 brain metastases 20.
Three other studies looked at WBRT and radiosurgery as
compared with radiosurgery alone for patients with 1–3
brain metastases 67, 1–4 brain metastases 68, and single
or multiple brain metastases 69. One study focused on
QOL and the patients’ perspectives regarding manage-
ment-related complications in addition to the radiosur-
gery 68. Another study investigated the survival and QOL
of patients who were randomized to WBRT with
efaproxiral or to WBRT alone 70. Six other studies exam-
ined the role of QOL or patient-rated symptoms when
assessing the effectiveness of WBRT 17,71–75. Two stud-
ies assessed the neurocognitive function (NCF) of pa-
tients who had been treated with WBRT and a
radiosensitizer 76 or with WBRT alone 27. Lastly, one
study investigated both NCF and QOL of patients treated
with WBRT 77.
3.3 Study Outcomes
Tables I–IX present the outcomes of the trials outlined
in the previous subsection. The endpoints of overall
median survival, overall survival at 6 months, 1-year
local control, overall response rate, QOL, neurologic
function, and symptom control are reported when
available. The number of QOL instruments used in each
study is also recorded.QUALITY OF LIFE IN BRAIN METASTASES RADIATION TRIALS
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3.4 QOL Instruments
A total of 24 different QOL instruments, including per-
formance scales, study-designed performance instru-
ments, validated QOL instruments, study-designed QOL
assessments, neurologic function scales, study-de-
signed neurologic instruments, and NCF tests were used
in the trials (Tables X–XIV). Six studies did not use any
QOL measures 20,43,60–62,78. The most commonly used
instruments were the KPS scale (n = 33) and various
forms of neurologic function classification (n = 21).
The number of QOL instruments used in each study
varied from 0 to 8, but most of the studies used 1 (n =
26, 43%) or 2 (n = 21, 34%) instruments. Of the 23
different instruments used, 8 (35%) assessed QOL, 7
(30%) assessed NCF, 5 (22%) assessed performance
status, and 3 (13%) assessed neurologic function.
Of the 8 QOL instruments used, 2 were study-de-
signed assessments 68,74. Kondziolka et al. 68 designed
a 10-item survey to ask patients treated with WBRT
and radiosurgery or with radiosurgery alone about their
treatment perceptions, side effects (hair loss, fatigue,
memory, mood or affect, intellectual concentration,
employment), activity level, and overall satisfaction.
This survey was used in a patient population in which
90% of the patients had a KPS status of 90 or 100. After
WBRT, the side effects reported were alopecia (88%);
excess fatigue (85%); problems with short-term
memory (72%), long-term memory (33%), and
TABLE X Frequency of instruments used in clinical trials measuring
quality of life (QOL) in patients with brain metastases
                                  Instrument Frequency
Karnofsky performance status 33
Neurologic function classification 21
ECOG (World Health Organization) performance scores 11
General Performance Status 5
Mini Mental Status Examination 5
Study-designed performance instrument 22,23,40,50 4
Barthel index of activity of daily living 2
Controlled Oral Word Association test 2
Hopkins Verbal Learning Test 2
Spitzer quality of life index 2
Study-designed QOL assessment 68,74 2
Trailmaking A and B 2
Edmonton Symptom Assessment Scale 1
EORTC Core Quality of Life Questionnaire 1
   with Brain Cancer Module 2
Functional Assessment of Cancer Therapy–General scale 1
   With Brain subscale 2
Grooved Pegboard 1
Mini Mental State Inventory (modified abbreviated version) 1
Order classification 1
Profile of Mood States–Short Form 1
Ruff 2 and 7 1
Study-designed neurologic instrument 71 1
ECOG = Eastern Cooperative Oncology Group; EORTC = European
Organization for Research and Treatment of Cancer.
TABLE XI  Frequency of instruments used in assessing quality of
life (QOL) in clinical trials
                        Instrument Frequency
Spitzer quality of life index 2
Study-designed QOL assessment 68,74 2
Edmonton Symptom Assessment Scale 1
EORTC Core Quality of Life Questionnaire 1
   with Brain Cancer Module 2
Functional Assessment of Cancer Therapy–General scale 1
   with Brain subscale 2
Profile of Mood States–Short Form 1
EORTC = European Organization for Research and Treatment of
Cancer.
TABLE XII  Frequency of performance score instruments used in
clinical trials
                         Instrument Frequency
Karnofsky performance status 33
ECOG (World Health Organization) performance score 11
General Performance Status 5
Study-designed performance instrument 22,23,40,50 4
Barthel index of activity of daily living 2
ECOG = Eastern Cooperative Oncology Group.
TABLE XIII   Frequency of neurologic function instruments used in
clinical trials
                Instrument Frequency
Neurologic function classification 21
Order classification 1
Study-designed neurologic instrument 71 1
TABLE XIV   Frequency of neurocognitive function instruments used
in clinical trials
                         Instrument Frequency
Mini Mental Status Examination 5
Controlled Oral Word Association test 2
Hopkins Verbal Learning Test 2
Trailmaking A and B 2
Grooved Pegboard 1
Mini Mental State Inventory (modified abbreviated version) 1
Ruff 2 and 7 1
concentration (61%); and depression (54%). Also, pa-
tients more frequently reported short-term memory
problems (p < 0.0001), long-term memory problems
(p = 0.03), and concentration problems (p = 0.0007)
when they had undergone both WBRT and radiosurgery
as compared with radiosurgery alone. More patients
considered radiosurgery a good treatment for them as
compared with WBRT (76% vs. 56%, p = 0.25) 68.WONG et al.
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Sehlen et al. 74 developed the Current Situation in
Personal Life questionnaire because previous trials had
indicated that psychological and sociodemographic
variables could influence survival in cancer patients 74.
These authors assessed patients (KPS > 70) who had
undergone WBRT for primary central nervous system
tumours or brain metastases; their instrument was de-
signed to assess important sociodemographic variables
and factors in the patients’ personal lives, such as mari-
tal status, number of children or people in the house-
hold, level of education, employment, family history
of cancer, symptoms, relationships with family and
friends, social life, hobbies, religion, and significant
events. Interestingly, the results showed that “living
with a spouse” had a statistically significant positive
influence on survival (p = 0.033) 74.
Addeo et al. 55, Bezjak et al. 71, and Sehlen et al. 74
used the Functional Assessment of Cancer Therapy—
General scale (FACT-G). This questionnaire is a vali-
dated instrument that evaluates the QOL of cancer
patients in 5 domains, including physical well-being (7
items), social or family well-being (7 items), relation-
ship with the physician (2 items), emotional well-be-
ing (5 items), and functional well-being (7 items) 79.
Sehlen and her colleagues showed that the overall
FACT-G score had a significant influence on survival
(p = 0.003) 74.
The FACT-G is often supplemented by site-specific
questionnaires such as the FACT–Brain subscale (FACT-
BR) as used by Bezjak et al. 71 and Addeo et al. 55 The
FACT-BR subscale contains 19 additional items per-
taining to patients with brain metastases specifically,
including symptoms, self-care, cognitive ability, and
ease in usual activities 79. Bezjak et al. 71 found that,
as compared with baseline, 8 of 23 patients showed
improvement and 15 patients showed deterioration in
assessed QOL using the FACT-G and FACT-BR question-
naires 1 month after palliative radiotherapy.
The full FACT-BR scale contains 53 questions (as
compared with the subscale, with its 19 questions).
Addeo et al. 55 used the FACT-G and selected 26 items
from the FACT-BR scale to assess QOL in patients who
underwent WBRT and temozolomide treatment. A sig-
nificant improvement in QOL was seen with the FACT-
G questionnaire (p < 0.0001). At baseline, 51% of
patients reported, positively, that they were “quite a
bit” or “very much” content with the quality of their
life; 49% reported, negatively, that they were “not at
all” or “a little bit” content with the quality of their
life. Three months after treatment, 79% were content
with their QOL, and 21% were not content.
Gerrard et al. 72, Yaneva et al. 75, and Roos et al. 39
used the European Organization for Research and Treat-
ment of Cancer (EORTC) Core Quality of Life Ques-
tionnaire (QLQ-C30). This general questionnaire
consists of 5 domains assessing functioning (physical,
role, cognitive, emotional, and social), 1 domain as-
sessing global QOL, 3 domains assessing common
symptoms (fatigue, pain, nausea or vomiting), 5 single
items assessing other symptoms (dyspnea, insomnia,
anorexia, constipation, and diarrhea), and 1 item as-
sessing financial impact.
Yaneva et al. 75 evaluated the QOL of patients with
a KPS greater than 70 before and after WBRT treat-
ment. A significant improvement was evident after
radiotherapy in all domains of functioning and in all
symptoms with the exception of dyspnea, diarrhea, and
financial difficulties. A significant improvement in
health-related QOL was also reported (p < 0.0001).
Gerrard et al. 72 and Roos et al. 39 used the supple-
mentary Brain Cancer Module (BCM) in addition to the
EORTC QLQ-C30. However, the BCM was designed for
patients with primary brain tumour. It consists of 20
questions that assess side effects of treatment, outlook
for the future, and common symptoms 80. Validation
of this instrument in patients with brain metastases has
not been reported.
When using the EORTC QLQ-C30 and BCM, Gerrard
et al. 72 experienced difficulties with data collection
and found that the questionnaires were lengthy and
demanding, particularly for their poor-prognosis group.
From the 18 patients analyzed in their first study, high
levels of fatigue and drowsiness were seen throughout
the study period (baseline to 8 weeks) and only 1 pa-
tient and 2 patients improved in QOL at 2 weeks and 4
weeks respectively. Their second study, which also used
the EORTC QLC-30 and BCM 20, was terminated pre-
maturely because of difficulties with data collection.
Improvement in QOL was not evident in any of the 6
patients accrued. Subsequently, in a third study, these
authors simplified their QOL assessment by asking only
the global health score and global QOL items of the
questionnaire. Of 14 patients, 7 experienced transient
improvements at some stage following WBRT.
Similarly, the randomized study of WBRT or con-
trol group post surgery or post radiosurgery by Roos et
al. 39 was also terminated prematurely because of its
slow accrual. As a result of the small sample size (n =
19), the investigators did not conduct a detailed QOL
analysis. They found that the differences in the global
health scores and global QOL scores between the two
study arms were nonsignificant at 2 months (p = 0.94)
and at 5 months (p = 0.50). The investigators concluded
that their study did not indicate that WBRT caused dete-
rioration in overall health or overall QOL.
Chow et al. 17 used the Edmonton Symptom As-
sessment System (ESAS) in their study of patient-rated
symptoms in patients with brain metastases treated with
WBRT. The ESAS is a validated instrument designed
for patients receiving palliative care. It evaluates 9
symptoms, including global pain, nausea, anxiety, de-
pression, tiredness, drowsiness, sense of well-being,
appetite, and shortness of breath. Each symptom is
rated on a scale from 0 to 10, where 0 represents ab-
sence of the symptom and 10 represents the worst
possible symptom. The ESAS has been shown to be a
quick tool to use and to predominantly reflect the physi-
cal well-being of the patient 81. In the study by ChowQUALITY OF LIFE IN BRAIN METASTASES RADIATION TRIALS
40 40 40 40 40
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and colleagues, 19%, 20%, and 15% of the patients
died during the first, second, and third month following
WBRT. The study population had statistically signifi-
cant deterioration in the mean differences between their
1-year follow-up and baseline scores for fatigue (1.0 to
1.8), drowsiness (1.2 to 1.8), and appetite (2.2 to 2.4).
Mintz et al. 29 and Scott et al. 70 used the Spitzer
Quality of Life index (Spitzer Q-L index). This vali-
dated instrument is composed of 5 domains: general
activity, daily living, health, support, and outlook. Each
domain is rated from 0 to 2 and each score is accom-
panied by verbal descriptions. For example, for the
health domain, the patient could report either feeling
well or “great” most of the time (score 2), lacking in
energy or being not entirely “up to par” occasionally
(score 1), or feeling very ill or “lousy,” weak and
washed out for most of the week (score 0) 82.
Mintz et al. 29 conducted a controlled trial in which
patients with a single brain metastasis were randomized
to either WBRT and surgery or to WBRT alone. When
comparing the two study arms, the mean QOL scores
were not significantly different at either of the study
periods analyzed (1–3 months and 4–6 months).
Scott et al. 70 assessed the QOL of patients
randomized to WBRT with efaproxiral or to WBRT alone.
At the 6-month follow-up as compared with baseline,
patients in the WBRT and efaproxiral arm had higher
Spitzer Q-L scores than did the patients in the WBRT
arm (p = 0.019). The authors also indicated that a score
of 7 or better out of 10 before treatment was a signifi-
cant predictor of overall survival. Patients with a score
of 7 or better experienced a 48% reduction in death
rate (p = 0.0079).
Regine et al. 77 used the Profile of Mood States–
Short Form (POMS-SF), a 30-item questionnaire organ-
ized into 6 mood scales: tension–anxiety,
depression–dejection, anger–hostility, vigour–activity,
fatigue–inertia, and confusion–bewilderment. The in-
dividual scales are combined to achieve an indicator
of overall mood. A higher mood disturbance score in-
dicates greater mood disturbance 77. Although compli-
ance rates for completion of the POMS-SF was high
before treatment (95% or more), at treatment comple-
tion (84% or more), and at 1 month after treatment
(70% or more), the results of the questionnaire were
not reported because patient mood was not the primary
objective of the study 77.
3.5 Performance Evaluation
The KPS (discussed earlier) was the tool most com-
monly used to assess performance status in thirty-three
studies. Results from Patchell et al. 34 are highlighted,
because these authors used the KPS as a measurement
of QOL when comparing patients with a single brain
metastasis who had undergone either surgery and WBRT
or WBRT alone. The length of time that KPS scores re-
mained at 70 or better was used as a determinant of
QOL. Patients in the surgery and WBRT arm maintained
KPS scores of 70 or better for much longer than did
patients who received radiation alone (38 weeks vs. 8
weeks, p < 0.005). In a prospective study, Li et al. 38
compared the outcomes of 3 treatment arms in patients
with a single brain metastasis and a KPS score of 60 or
better. An increase in KPS score was seen in all 3 treat-
ment arms: 88.9% (n = 16), 87.0% (n = 20), and 48.3%
(n = 14) in patients who underwent radiosurgery in com-
bination with WBRT, radiosurgery alone, and WBRT alone
respectively. A greater improvement in KPS was seen
in patients treated with radiosurgery alone or with ra-
diosurgery in combination with WBRT.
A study by Rosenman et al. 63 found that elective
radiation could improve the QOL of patients with small-
cell lung carcinoma, although it did not increase the
patients’ survival. All patients initially received a stand-
ard course of WBRT. After that course of treatment, 28
patients received elective radiation, and 24 patients
received radiation only when brain metastases occurred
(“therapeutic radiation”). A KPS score above 60 was
used by the investigators as a measure of QOL. Pa-
tients in the electively radiated arm maintained a KPS
score greater than 60 for a mean time of 10 months as
compared with a mean time of 6 months for patients in
the therapeutically radiated arm.
The Eastern Cooperative Oncology Group (ECOG)
evaluation was used in eleven of the studies to deter-
mine performance status. Unlike the KPS, which ranges
from 0 to 100, the ECOG is simpler. It ranges from 0 to
4, where 0 stands for “normal activity” and 4 means
“unable to get out of bed.” Roos et al. 39 used ECOG as
a part of their QOL assessment (baseline vs. first fol-
low-up) when comparing patients randomized to WBRT
or to observation after surgery or radiosurgery. No sig-
nificant difference was found between the two study
arms (p = 0.80).
Five of the studies used the General Performance
Status (GPS), which ranges from 1, which means “nor-
mal,” to 5, which means “100% bedridden.” Also, two
of the studies used the Barthel index of activity of daily
living, which is a validated measure for patients with
neurologic disability. Its questions focus on physical
performance in 10 areas: feeding, transfers from bed
to chair and back, grooming, toilet use, bathing, mo-
bility, climbing stairs, dressing, stool control, and blad-
der control.
Finally, four of the studies designed their own scales
to evaluate performance status 22,23,40,50. For exam-
ple, Horton et al. 40 measured performance status us-
ing a scale from 0 (“normal performance”) to 4
(“completely bedridden”). Kurtz et al. 50 measured
performance status on a scale from 0 to 100, where
scores from 70 to 100 indicated ambulatory patients
and scores under 70 indicated non-ambulatory patients.
Harwood et al. 22 classified the functional status of
their patients by level I, II, III, and IV, where level I
meant that the patient was “intellectually and physi-
cally able to work with neurological abnormalities minor
or absent” and level IV meant the patient had “profoundWONG et al.
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neurologic disability.” Noordijk and colleagues assessed
the general well-being of the patients by designing a
functionally independent survival tool 23. Patients were
considered to be functionally independent as long as
their score on the ECOG scale was 1 or lower (sympto-
matic, but almost completely independent) and their
score on a version of a neurologic function classifica-
tion was 1 or lower (patient can perform normal ac-
tivities with minimal difficulties).
3.6 Evaluation of Neurologic Function and
Symptoms
In 23 studies (Table XIII), a measure of the neurologic
function and symptoms of the patients was reported.
Various versions of a neurologic functional classifica-
tion or scale was used in 20 reports. Bezjak et al. 71
modelled an assessment tool after symptom items in-
cluded in the FACT-BR and the BCM 20. This patient-
rated assessment tool consisted of 16 items specific to
patients with brain metastases. Symptoms were sub-
divided into raised intracranial pressure (3 items), ef-
fects associated with steroid use (4 items), possible
subacute side effects (4 items), and effects associated
with brain metastases (5 items). Robinet et al. 7 used
the order classification to record the neurologic status
of the patients.
3.7 Neurocognitive Function
Li et al. 76, Murray et al. 27, Regine et al. 77, Roos et
al. 39, Scott et al. 70, and Sehlen et al. 74 assessed NCF
in their studies, five of which included the Mini Mental
Status Examination (MMSE) as an instrument 27,39,70,74,77
(Table XIV). The MMSE is a validated and easily ad-
ministered tool consisting of 11 items designed to test
cognitive function. It includes tests of the patient’s
knowledge of orientation (1 item); memory (2 items);
immediate recall (1 item); attention, concentration,
and calculation (1 item); and aphasia and apraxia (4
items) 27. Roos et al. 39 compared the MMSE scores of
patients with a single brain metastasis randomized to
WBRT or to observation post surgery or post radiosur-
gery. Although the study was terminated prematurely
because of slow accrual, no significant difference was
found between the two study arms at the 12-month fol-
low-up (p = 0.50).
The Hopkins Verbal Learning Test, which was used
by Li et al. 76 and Regine et al. 77 is a memory test
instrument and includes items for short- and long-term
recall and word recognition 83. The Controlled Oral
Word Association test used by Li et al. 76 and Regine
et al. 77 assesses language and executive function skills
where the patient’s task is to produce, in 1 minute, as
many words as possible beginning with a specific letter.
Additionally, trials by Li et al. 76 and Regine et al. 77
used the trail-making test designed to test visual motor
speed and executive function 83.
Regine et al. 77 included the Ruff 2 and 7 Test as a
component of their NCF test battery to assess neglect,
attention, and concentration. Li et al. 76 assessed mo-
tor speed, visual–motor coordination, and single-hand
dexterity with the Grooved Pegboard Test. Sehlen et
al. 74 used a modified abbreviated version of the Mini
Mental State Inventory to evaluate mental capacity.
4. DISCUSSION
In recent years, QOL has become an increasingly im-
portant outcome in cancer trials. To date, fourteen tri-
als on brain metastases that included an evaluation of
the study population’s QOL have been published. Three
of the trials used the FACT-G and FACT-BR instruments,
three used the EORTC QLQ-C30 and BCM 20 instruments,
two designed QOL instruments specifically for the trial,
one used the ESAS instrument, two used the Spitzer Q-L
index, and three used the KPS as a tool to evaluate QOL.
Our findings suggest that, although numerous QOL ques-
tionnaires exist, no standard questionnaire is currently
used to assess QOL in patients with brain metastases.
Currently, the use of these different questionnaires does
not allow for a comparison of QOL across trials. A stand-
ard tool would be beneficial for comparisons across
trials and for performing meta-analyses.
Our literature review shows that certain param-
eters of QOL deteriorate after WBRT 17,71,72. Chow et
al. 17 concluded that the ESAS domains of fatigue, drow-
siness, and appetite worsened after WBRT in their pa-
tients (baseline median KPS: 60; range: 20–90). In the
study by Gerrard et al. 72, 10 of the 38 patients (26%;
95% confidence interval: 13%–43%) improved in at least
one of the following parameters during the study pe-
riod: QOL score, Barthel index of activity of daily liv-
ing, or KPS 8 weeks after WBRT. However, 14 of 15
patients had deterioration in at least one of these pa-
rameters. Using the FACT-BR questionnaire, Bezjak et
al. 71 also found deterioration in QOL from baseline to
1 month, but the difference was not statistically sig-
nificant (p = 0.13). These findings have led authors to
question whether patients with poor prognosis benefit
from radiotherapy in terms of effect on QOL and symp-
tom experiences 17,72.
For patients with a better prognosis, the results of
Addeo et al. 55, Yaneva et al. 75, and Scott et al. 70
showed that certain parameters of QOL significantly
improved after WBRT. Addeo et al. 55 used the FACT-G
and 26 of the FACT-BR scale items to assess QOL in
patients who underwent WBRT and temozolomide treat-
ment. A significant improvement in QOL was seen (p <
0.0001). Three months after treatment, 79% were con-
tent with their quality of life, and 21% were discontent
(compared with 51% positive respondents and 49%
negative respondents at baseline).
Using a recursive partitioning analysis (RPA) based
on the KPS, the Radiation Therapy Oncology group es-
tablished three prognostic classes for patients with brain
metastases according to tumour, primary tumour sta-
tus, presence of extracranial metastases, and age. Class
I included patients with a KPS of 70 or better, age belowQUALITY OF LIFE IN BRAIN METASTASES RADIATION TRIALS
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65 years, no extracranial metastases, and a controlled
primary tumour; these patients had a median survival
of 7.1 months. In comparison, patients with a KPS be-
low 70 are class III with a median survival of 2.3 months.
All other patients belong to class II, with a median sur-
vival of 4.2 months.
Addeo et al. 55 included a high number of patients
in the RPA classes I (n = 21, 36%) and II (n = 22, 37%).
That patient population differed greatly from the popu-
lation included in the study by Bezjak et al. 71, where
3, 31, and 41 patients were in RPA classes I, II, and III
respectively.
Yaneva et al. 75 used the EORTC QLQ-C30 in a pa-
tient population who underwent WBRT. Significant im-
provements in functional indicators, symptoms, and
health-related QOL were found after WBRT. Those re-
sults differ from the findings of Gerrard et al. 72, who
also used the EORTC QLQ-C30 questionnaire; however,
the population in their study satisfied at least two of
the following criteria: KPS below 70, more than 60 years
of age, or a primary tumour site other than breast. In
comparison, Yaneva et al. 75 selected patients who had
KPS scores above 70.
Scott et al. 70 randomized patients to WBRT with
efaproxiral or to WBRT alone, using the Spitzer Q-L
index as a measurement of QOL. At the 6-month fol-
low-up, patients who had received WBRT and
efaproxiral had higher QOL scores than did the patients
who had received WBRT alone (p = 0.019). This study
population also included patients with a better progno-
sis (only RPA class I and II patients were included). Of
the study population, 58% percent had a KPS score of
90–100, and 42% had a KPS score of 70–80.
One study found that certain parameters of QOL
did not deteriorate or improve after WBRT. Roos et al. 39
randomized patients to WBRT or to no additional treat-
ment post surgery or post radiotherapy. The EORTC glo-
bal health scores and global QOL scores were not
significant between the study arms at 2 months (p =
0.94) and at 5 months (p = 0.50). These patients also
had a fairly good prognosis: solitary brain metastasis
and 14, 4, and 1 of 19 patients in RPA classes I, II, and
III respectively. Although no improvement in QOL was
evident, the results also did not indicate that QOL dete-
riorated after patients received WBRT. Poor accrual and
low statistical power likely contributed to this outcome.
The present review found that few WBRT studies
included a measure of QOL as a primary endpoint. A
possible explanation is the difficulty in collecting data
in a population of patients whose life expectancy is short.
Patients with short survival and deterioration of health
often contribute to high attrition rates in brain metastases
QOL studies 17,72. For example, Bezjak et al. 71 found
that only 19% of patients had symptomatic improve-
ment and that 55% had either progressed in their illness
or had died at 1 month. Consequently, the drop-out bias
affecting research studies must be kept in mind: pa-
tients included in the results are those able to complete
follow-up assessments and are thus likely have a better
prognosis than are the patients lost to follow-up 11,71.
Scott et al. 70 found that the Spitzer Q-L index was a
better predictor of survival than the KPS was, and they
suggested the use of this QOL instrument in predicting
survival and assessing patient status. Sehlen and col-
leagues found that the overall FACT-G score had a statis-
tically significant correlation with survival (p = 0.003).
Although data collection is a challenge in this study popu-
lation, the results of Sehlen et al. 74 suggest that QOL is
a worthwhile endpoint to include in future brain
metastases trials and that it could possibly distinguish
patients with a longer expected survival.
The studies identified in this review used 55 dif-
ferent performance status assessment tools and 23 dif-
ferent neurologic function instruments. However, these
instruments were primarily used to categorize the pa-
tients into prognostic groups, to describe the study popu-
lation, or to act as exclusion criteria. The study by
Patchell et al. 34 was an exception: the authors used
the KPS to evaluate the QOL of patients before and af-
ter treatment. They determined QOL by the length of
time the KPS remained at 70 or higher. Their results
showed that the KPS scores of patients in the combined
radiotherapy and surgery arm were maintained for a
much longer period than were the scores of patients
who had undergone radiotherapy alone (38 weeks vs. 8
weeks, p < 0.005) 34. Similarly, Li et al. 38 compared
KPS scores from the day of treatment with scores from
the first follow-up visit to determine if different treat-
ments had an effect on the QOL of lung cancer patients
with a single brain metastasis. Improvements of 88.9%
(n = 16) and 87.0% (n = 20) respectively were seen in
the KPS scores of patients who underwent radiosur-
gery in combination with WBRT and radiosurgery alone.
In comparison, an improvement of 48.3% (n = 14) was
seen in patients who underwent WBRT alone. A study
by Rosenman et al. 63 investigated whether QOL im-
proved with elective radiation after a standard course
of WBRT in 28 patients (compared with 24 patients who
received radiation therapeutically). These authors de-
fined QOL as the length of time a patient’s KPS score
remained above 60. Patients in the electively radiated
arm maintained a KPS score above 60 for significantly
longer than did the patients in the therapeutically radi-
ated arm (10 months vs. 6 months).
The NCF is clearly an important concern for brain
metastases patients. Although the MMSE was the most
frequently used measure of NCF in the studies, it is
less sensitive to mild neurocognitive impairment and
may not identify subtle improvements 68,83. In addi-
tion, the MMSE has not been as thoroughly evaluated in
patients with brain metastases as compared with pa-
tients with primary brain tumours 83. Hence, studies
have designed NCF test batteries to thoroughly evalu-
ate the NCF of study patients 77,83. Li et al. 76 investi-
gated the NCF of patients who had been treated with a
radiosensitizer (gadolinium) and WBRT. Patients were
classified as “good” or “poor” responders depending
on whether their tumour reduction at 2 months wasWONG et al.
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above or below the population median reduction of 45%.
Their results showed that the “good” responders sur-
vived significantly longer than did the “poor” respond-
ers. Time to NCF deterioration was compared in the
“good” and “poor” responders, and results indicated
that patients with volume regression after radiation had
a longer delay before NCF deterioration. The authors
concluded that NCF and QOL correlated in their study
population and that efforts to prevent the worsening of
NCF could help maintain QOL 76.
5. CONCLUSIONS
Quality of life is an important outcome in the treat-
ment of patients diagnosed with brain metastases.
However, few clinical trials have focused on QOL as a
primary outcome. Common outcomes measured are
survival, response to treatment, symptomatic relief,
toxicity, and duration of independent function. The
present review finds that various management meth-
ods for brain metastases have been explored, and yet
median survival in this patient population has not im-
proved significantly. Thus, less-morbid treatment op-
tions that preserve or improve QOL in these patients
are important.
Our literature review found that a number of QOL
instruments have been used to evaluate patients with
brain metastases. Additional assessment tools, includ-
ing performance status tools, neurologic function as-
sessments, and NCF tests were also used in many
clinical trials to evaluate the well-being of patients.
Some studies have shown that certain parameters of
QOL deteriorate after WBRT in patients with poorer prog-
nosis, but other studies have shown that QOL in pa-
tients with better prognosis improve after WBRT.
Although a number of validated QOL questionnaires
specific to the concerns of metastatic brain cancer
patients have been developed, no standard question-
naire has currently been established for this patient
population, making comparisons of QOL across trials
difficult. Our findings emphasize the importance of
including QOL as an endpoint in future clinical trials so
as to better understand the role of QOL, especially for
improving treatment in patients with brain metastases.
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